Chemical Compound Review:
Prodiax 2-[3-[(4-bromo-2-fluoro- phenyl)methyl]-4...
Synonyms:
statil, PONALRESTAT, Ponalrestatum, Tocris-0847, CHEMBL7679, ...
- Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat. Sima, A.A., Prashar, A., Zhang, W.X., Chakrabarti, S., Greene, D.A. J. Clin. Invest. (1990)
- Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus. Boland, O.M., Blackwell, C.C., Clarke, B.F., Ewing, D.J. Diabetes (1993)
- Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Florkowski, C.M., Rowe, B.R., Nightingale, S., Harvey, T.C., Barnett, A.H. Diabetes (1991)
- Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor. Kawamura, I., Yamamoto, N., Sakai, F., Yamazaki, H., Naoe, Y., Inami, M., Manda, T., Shimomura, K. Anticancer Res. (1999)
- Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Pedersen, M.M., Christiansen, J.S., Mogensen, C.E. Diabetes (1991)
- Diabetic autonomic neuropathy in BB rats and effect of ARI treatment on heart-rate variability and vagus nerve structure. Zhang, W.X., Chakrabarti, S., Greene, D.A., Sima, A.A. Diabetes (1990)
- EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress. Nishinaka, T., Yabe-Nishimura, C. Free Radic. Biol. Med. (2001)
- Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. Malamas, M.S., Hohman, T.C., Millen, J. J. Med. Chem. (1994)
- Ponalrestat: a potent and specific inhibitor of aldose reductase. Ward, W.H., Sennitt, C.M., Ross, H., Dingle, A., Timms, D., Mirrlees, D.J., Tuffin, D.P. Biochem. Pharmacol. (1990)
- Impaired induction of nerve ornithine decarboxylase activity in the streptozotocin-diabetic rat is prevented by the aldose reductase inhibitor ponalrestat. Pekiner, C., McLean, W.G. Br. J. Pharmacol. (1990)
- Effects of diabetes on cholinergic transmission in two rat gut preparations. Lucas, P.D., Sardar, A.M. Gastroenterology (1991)
- Effect of aldose reductase inhibition and insulin treatment on retinal capillary basement membrane thickening in BB rats. Chakrabarti, S., Sima, A.A. Diabetes (1989)
- Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Yagihashi, S., Kamijo, M., Ido, Y., Mirrlees, D.J. Diabetes (1990)
- Identification and characterization of aldose reductase in cultured rat mesangial cells. Kikkawa, R., Umemura, K., Haneda, M., Kajiwara, N., Maeda, S., Nishimura, C., Shigeta, Y. Diabetes (1992)
- Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Mizisin, A.P., Calcutt, N.A., DiStefano, P.S., Acheson, A., Longo, F.M. Diabetes (1997)
- Adenosine triphosphatase in nerves and ganglia of rats with streptozotocin-induced diabetes or galactosaemia; effects of aldose reductase inhibition. Lambourne, J.E., Brown, A.M., Calcutt, N., Tomlinson, D.R., Willars, G.B. Diabetologia (1988)
- The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Soulis-Liparota, T., Cooper, M.E., Dunlop, M., Jerums, G. Diabetologia (1995)
- Diabetes-induced changes in cardiac beta-adrenoceptor responsiveness: effects of aldose reductase inhibition with ponalrestat. Austin, C.E., Chess-Williams, R. Br. J. Pharmacol. (1991)
- Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats. Kador, P.F., Inoue, J., Secchi, E.F., Lizak, M.J., Rodriguez, L., Mori, K., Greentree, W., Blessing, K., Lackner, P.A., Sato, S. Exp. Eye Res. (1998)
- Enteric neuropeptides in streptozotocin-diabetic rats; effects of insulin and aldose reductase inhibition. Belai, A., Calcutt, N.A., Carrington, A.L., Diemel, L.T., Tomlinson, D.R., Burnstock, G. J. Auton. Nerv. Syst. (1996)
- Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Cameron, N.E., Cotter, M.A., Dines, K.C., Maxfield, E.K., Carey, F., Mirrlees, D.J. Diabetologia (1994)
- Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats. Cameron, N.E., Cotter, M.A. Br. J. Pharmacol. (1992)
- Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy. Valensi, P., Attali, J.R., Gagant, S. Diabet. Med. (1993)
- Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy. Ranganathan, S., Krempf, M., Feraille, E., Charbonnel, B. Diabète & métabolisme. (1993)